Telmisartan in the management of the cardiovascular disease continuum in the real world setting in India

Background: The cardiovascular disease continuum (CVDC) is a progressive sequence of events that may lead to advanced cardiovascular (CV) disease. This questionnaire-based study aims to provide insights into real-world effectiveness, safety and adherence of telmisartan in managing hypertension (HT) and associated CV conditions.

Methods: This questionnaire-based study was conducted among Indian HCPs from between November 2024 to February 2025.  A questionnaire comprising 16 questions explored preferences of health care professionals (HCPs) for use of telmisartan in last 10 patients with CVDC.

Results: A total of 49 HCP were included in this study. The 65.31% of HCPs newly diagnosed < 5 patients with HT. Maximum HCPs (69.39%) noted diabetes mellitus has risk factor. In patients with long standing hypertension, both reduction of left ventricular hypertrophy and no progression to angina was noted by 79.59% of HCPs after treatment. A substantial majority of 69.39% of HCPs reported telmisartan controlled blood pressure (BP) for 24 hours. The ambulatory BP recording was done for 2 patients by 51.02% of HCPs. The 40.82% of HCPs reported single patient had undergone percutaneous coronary intervention. Well controlled BP was recorded by 51.02% HCPs. The 51.02% of HCPs indicated that 50% of diabetic patients reached their target BP in spite of the comorbid disease. Metoprolol was prescribed in combination therapy by 59.18% of HCPs. All the HCPs rated telmisartan efficacy, safety and adherence to treatment as excellent and good.

Conclusion: This study revealed insights into telmisartan's efficacy, safety and adherence in management of HT.